Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.

Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM.

Cancer. 2010 Mar 1;116(5):1234-42. doi: 10.1002/cncr.24816.

2.

The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer.

Wu MF, Hilsenbeck SG, Tham YL, Kramer R, Elledge RM, Chang JC, Friedman LC.

Breast Cancer Res Treat. 2009 Nov;118(2):369-75. doi: 10.1007/s10549-009-0425-y. Epub 2009 Jun 3.

PMID:
19495957
3.

Association of surgery with improved survival in stage IV breast cancer patients.

Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM.

Ann Surg. 2008 May;247(5):732-8. doi: 10.1097/SLA.0b013e3181656d32.

PMID:
18438108
4.

Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.

Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC.

Clin Cancer Res. 2006 Sep 1;12(17):5047-54.

5.

The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause.

Tham YL, Sexton K, Weiss HL, Elledge RM, Friedman LC, Kramer RM.

J Support Oncol. 2006 Jun;4(6):295-8, 304.

PMID:
16805332
6.

Tales from a targeted therapy.

Elledge RM.

J Clin Oncol. 2006 Mar 20;24(9):1323-5. Epub 2006 Feb 27. No abstract available.

PMID:
16505410
7.

Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.

Mohsin SK, Allred DC, Osborne CK, Cruz A, Otto P, Chew H, Clark GM, Elledge RM.

Breast Cancer Res Treat. 2005 Dec;94(3):205-11.

PMID:
16267611
8.

Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.

Tham YL, Gomez LF, Mohsin S, Gutierrez MC, Weiss H, Hilsenbeck SG, Elledge RM, Chamness GC, Osborne CK, Allred DC, Chang JC.

Breast Cancer Res Treat. 2005 Dec;94(3):279-84.

PMID:
16261403
9.

Premalignant and in situ breast disease: biology and clinical implications.

Arpino G, Laucirica R, Elledge RM.

Ann Intern Med. 2005 Sep 20;143(6):446-57.

PMID:
16172443
10.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

PMID:
16145046
11.

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.

Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF.

Cancer. 2005 Jul 15;104(2):236-9.

12.

BRCA1 in clinical breast cancer.

Osborne CK, Elledge RM, Brown PH, Hilsenbeck SG.

Breast Dis. 1998 Apr;10(1-2):77-88. No abstract available.

PMID:
15687551
13.

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.

Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM.

Clin Cancer Res. 2004 Sep 1;10(17):5670-6.

14.

Lobular neoplasia on core-needle biopsy--clinical significance.

Arpino G, Allred DC, Mohsin SK, Weiss HL, Conrow D, Elledge RM.

Cancer. 2004 Jul 15;101(2):242-50.

15.

Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.

Arpino G, Bardou VJ, Clark GM, Elledge RM.

Breast Cancer Res. 2004;6(3):R149-56. Epub 2004 Feb 17.

16.

Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results.

Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A Jr, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC.

Clin Breast Cancer. 2003 Dec;4(5):348-53.

PMID:
14715110
17.

A roundtable discussion of aromatase inhibitors as therapy for breast cancer.

Allred DC, Baum M, Buzdar AU, Carlson RW, Dowsett M, Elledge RM, Gradishar WJ, Grana G, Howell A, Mamounas EP.

Breast J. 2003 May-Jun;9(3):213-22. Review.

PMID:
12752630
18.
19.

Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer.

Arpino G, Nair Krishnan M, Doval Dinesh C, Bardou VJ, Clark GM, Elledge RM.

Ann Oncol. 2003 Feb;14(2):233-41.

PMID:
12562650
20.

Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.

Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM.

Cancer. 2003 Feb 1;97(3):545-53.

21.

Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome.

Arpino G, Clark GM, Mohsin S, Bardou VJ, Elledge RM.

Cancer. 2002 Apr 15;94(8):2119-27. Review.

22.

Clinical management of women with genomic BRCA1 and BRCA2 mutations.

Chang J, Elledge RM.

Breast Cancer Res Treat. 2001 Sep;69(2):101-13. Review.

PMID:
11759816
23.

Ductal lavage for detection of cellular atypia in women at high risk for breast cancer.

Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB.

J Natl Cancer Inst. 2001 Nov 7;93(21):1624-32.

PMID:
11698566
25.

RESPONSE: Re: Tumor Characteristics and Clinical Outcome of Elderly Women With Breast Cancer.

Diab SG, Elledge RM, Clark GM.

J Natl Cancer Inst. 2001 Jan 3;93(1):65-66. No abstract available.

PMID:
11136847
26.

Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients.

Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC, Elledge RM.

J Clin Oncol. 2000 May;18(9):1906-13.

PMID:
10784631
27.

Tumor characteristics and clinical outcome of elderly women with breast cancer.

Diab SG, Elledge RM, Clark GM.

J Natl Cancer Inst. 2000 Apr 5;92(7):550-6.

PMID:
10749910
28.

Caution concerning micrometastatic breast carcinoma in sentinel lymph nodes.

Allred DC, Elledge RM.

Cancer. 1999 Sep 15;86(6):905-7. No abstract available.

PMID:
10491512
29.

Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas.

Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM.

J Clin Oncol. 1999 May;17(5):1442-8.

PMID:
10334529
30.

Prognostic and predictive value of p53 and p21 in breast cancer.

Elledge RM, Allred DC.

Breast Cancer Res Treat. 1998;52(1-3):79-98. Review.

PMID:
10066074
31.

Models for early chemoprevention trials in breast cancer.

Fabian CJ, Kimler BF, Elledge RM, Grizzle WE, Beenken SW, Ward JH.

Hematol Oncol Clin North Am. 1998 Oct;12(5):993-1017. Review.

PMID:
9888018
32.
33.

Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.

Diab SG, Hilsenbeck SG, de Moor C, Clark GM, Osborne CK, Ravdin PM, Elledge RM.

J Clin Oncol. 1998 May;16(5):1655-60.

PMID:
9586875
34.

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK.

Clin Cancer Res. 1998 Jan;4(1):7-12.

35.

bcl-2 and apoptosis in lymph node positive breast carcinoma.

Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC.

Cancer. 1998 Apr 1;82(7):1296-302.

PMID:
9529021
36.

Oestrogen receptors and breast cancer.

Elledge RM, Osborne CK.

BMJ. 1997 Jun 28;314(7098):1843-4. No abstract available.

37.

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.

Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK.

J Clin Oncol. 1997 May;15(5):1916-22.

PMID:
9164202
38.

WAF1/CIP1 protein expression in human breast tumors.

Diab SG, Yu YY, Hilsenbeck SG, Allred DC, Elledge RM.

Breast Cancer Res Treat. 1997 Apr;43(2):99-103.

PMID:
9131264
39.

Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick?

Elledge RM.

J Natl Cancer Inst. 1996 Feb 21;88(3-4):141-3. No abstract available.

PMID:
8632483
40.

Life and death by p53.

Elledge RM, Lee WH.

Bioessays. 1995 Nov;17(11):923-30. Review.

PMID:
8526886
41.

p53 mutation and tamoxifen resistance in breast cancer.

Elledge RM, Lock-Lim S, Allred DC, Hilsenbeck SG, Cordner L.

Clin Cancer Res. 1995 Oct;1(10):1203-8.

42.

Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.

Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, et al.

J Natl Cancer Inst. 1995 Aug 16;87(16):1254-6. No abstract available.

PMID:
7563172
43.

Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer.

Elledge RM, Clark GM, Hon J, Thant M, Belt R, Maguire YP, Brown J, Bartels P, Von Hoff DD.

J Clin Oncol. 1995 Feb;13(2):419-23.

PMID:
7844603
44.

Rising levels of estrogen receptor in breast cancer over 2 decades.

Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM.

Cancer. 1994 Sep 1;74(5):1601-6.

PMID:
8062191
45.
46.

Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.

Elledge RM, Clark GM, Chamness GC, Osborne CK.

J Natl Cancer Inst. 1994 May 4;86(9):705-12.

PMID:
7908990
47.

Evaluation of thymidylate synthase RNA expression by polymerase chain reaction.

Elledge RM, Okuyama N, Fitzgerald SD, Fugua SA.

Mol Cell Probes. 1994 Feb;8(1):67-72.

PMID:
8028610
48.

The p53 tumor suppressor gene in breast cancer.

Elledge RM, Allred DC.

Breast Cancer Res Treat. 1994;32(1):39-47. Review.

PMID:
7819584
49.

Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients.

Elledge RM, Ciocca DR, Langone G, McGuire WL.

Cancer. 1993 Apr 15;71(8):2499-506.

PMID:
8095853
50.

Prognostic factors and therapeutic decisions in axillary node-negative breast cancer.

Elledge RM, McGuire WL.

Annu Rev Med. 1993;44:201-10. Review.

PMID:
8476242

Supplemental Content

Loading ...
Support Center